Effect of Elimination of Acid Reflux on Epithelial Cell Proliferative Activity of Barrett Esophagus
- 1 January 2000
- journal article
- Published by Taylor & Francis in Scandinavian Journal of Gastroenterology
- Vol. 35 (12) , 1238-1244
- https://doi.org/10.1080/003655200453557
Abstract
Barrett esophagus (BE) is a premalignant condition resulting from chronic acid gastroesophageal reflux and is associated with increased epithelial cell proliferation. Elimination of acid reflux might decrease cancer risk by affecting cell proliferation in BE. The effect of elimination of acid reflux on epithelial cell proliferation in BE was studied. Forty-five patients with long segment Barrett esophagus were treated in a randomized 2-year follow-up study with either omeprazole 40 mg b.i.d. (OME) or ranitidine 150 mg b.i.d. (RAN) and were compared for the effect on epithelial cell proliferation. Biopsies were taken 3 cm above the GE junction and just below the Z-line, at 0, 3, 9, and 24 months. Epithelial cell proliferation was determined by in vitro labeling with 5-bromo-2-deoxyuridine and immunohistochemistry. Labeling indices (LI) were established for luminal and crypt epithelium separately. Ambulatory 24-h esophageal pH-metry was performed at 0 and 3 months. Comparisons were made for the timeframes 0-3 months, 3-24 months, and 0-24 months. OME reduced mean acid reflux to 0.1 %/24 h, RAN to 9.4%. In the distal and the proximal biopsies, change in LI after 3 months was n.s. at either level for both treatments. In the distal biopsies (OME 22, RAN 23 patients) luminal LI increased significantly for RAN from 3 to 24 months (+12.64% month, mean area under the curve (AUC)), while that for OME remained stable, RAN versus OME P < 0.05. Crypt LI increased in both groups, only in RAN significantly so (+30.75% month), RAN versus OME n.s. In the proximal biopsies luminal LI at 24 months (OME 20, RAN 21 patients) had increased slightly but not significantly in RAN (+8.86% month), RAN versus OME n.s., whereas in the crypts LI in OME it had increased significantly (+28.80% month), OME versus RAN n.s. Elimination of acid reflux resulted in a stabilization of luminal cell proliferative activity of Barrett epithelium in the distal esophagus, whereas this activity increased during continued acid reflux. Whether this finding has any implication for the cancer risk in Barrett esophagus remains to be seen.Keywords
This publication has 23 references indexed in Scilit:
- Regression of columnar‐lined (Barrett’s) oesophagus with omeprazole 40 mg daily: results of 5 years of continuous therapyAlimentary Pharmacology & Therapeutics, 1999
- Barrett's esophagus: Whom to screen? Still an unanswered questionGastroenterology, 1998
- Contribution of acid and duodenogastrooesophageal reflux to oesophageal mucosal injury and symptoms in partial gastrectomy patientsGut, 1997
- The diagnosis of Barrett's esophagus: goblets, goblets, gobletsGastrointestinal Endoscopy, 1996
- The value of p53 and Ki67 as markers for tumour progression in the Barrett's dysplasia-carcinoma sequenceSurgical Oncology, 1995
- Barrett's Oesophagus and CarcinomaScandinavian Journal of Gastroenterology, 1993
- Rectal cell proliferation and colorectal cancer risk level in patients with nonfamilial adenomatous polyps of the large bowelCancer, 1991
- Proliferation rate of colonic mucosa in normal subjects and patients with colonic neoplasms: a refined immunohistochemical method.Journal of Clinical Pathology, 1990
- Effect of Added Dietary Calcium on Colonic Epithelial-Cell Proliferation in Subjects at High Risk for Familial Colonic CancerNew England Journal of Medicine, 1985
- Cell proliferation kinetics in the gastric remnantEuropean Journal of Cancer and Clinical Oncology, 1985